Management and Key Opinion Leaders to Review Product Pipeline and
Development Strategy
Webcast Scheduled for 12:15 p.m. (ET) On Wednesday, September 10,
2008
ALAMEDA, Calif., Sept. 3, 2008 (GLOBE NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, will webcast presentations live from their Research Day on Wednesday, September 10, beginning at 12:15 p.m. ET.
PRESENTATIONS
* A Strategic Company Overview, by Kenneth Chahine, Ph.D., J.D.,
President and Chief Executive Officer, Avigen
* An Overview of AV650, by Robert Elfont, M.D., Ph.D., Associate
Vice President of Clinical Development, Avigen
* AV650, the German Neurologist Experience, by Michael Coffee, Chief
Business Officer, Avigen
* An Overview of AV411 (ibudilast), by Kirk Johnson, Ph.D., Vice
President, Research and Development, Avigen
* Pharmacotherapies for Drug Addiction, by Frank Vocci, Ph.D.,
Director, Division of Pharmacotherapies and Medical Consequences
of Drug Abuse, National Institute on Drug Abuse
* Opioid Dependence and Withdrawal and AV411 Assessment, by Sandra
Comer, Ph.D., Associate Professor of Clinical Neurobiology at New
York State Psychiatric Institute and Columbia University
Avigen will conduct a live webcast of the presentations beginning at 12:15 p.m. To access the webcast over the Internet, please go to www.avigen.com. An archive of the presentations will be available through Avigen's website shortly after the conclusion of the sessions.
About Avigen
Avigen is a biopharmaceutical company focused on developing and commercializing small molecule therapeutics to treat serious neurological disorders, including neuropathic pain and neuromuscular spasm and spasticity. Avigen's strategy is to complete the requirements of clinical development for each of the candidates in its product pipeline, and continue to look for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing, with the goal of becoming a fully integrated commercial biopharmaceutical company that remains committed to its neurology products. Avigen is currently developing AV650 for spasticity and neuromuscular spasm and AV411 for neuropathic pain. Additionally, the company is advancing AV513, a novel therapy for the treatment of multiple bleeding disorders, including hemophilia A and B, toward clinical trials. For more information about Avigen, consult the company's website at www.avigen.com.
The Avigen, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2981
Statement under the Private Securities Litigation Reform Act
This press release contains forward-looking statements, which include, among others, statements relating to Avigen's intention of completing the requirements of clinical development for each of the candidates in its product pipeline; looking for opportunities to expand its pipeline through a combination of internal research, acquisitions, and in-licensing; and becoming a fully integrated commercial biopharmaceutical company. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected in these forward-looking statements. These risks and uncertainties include those detailed in reports filed by Avigen with the Securities and Exchange Commission, including Avigen's quarterly report on Form 10-Q for the period ended June 30, 2008, under the caption "Risks Related to Our Business" in Item 2 of Part I of that report, which was filed with the SEC on August 11, 2008.